n engl j m
What was the primary outcome measured in the trial?
Apuntes
•Background Limited evidence supports the simultaneous initiation of sodium–glucose cotransporter-2 (SGLT2) inhibitors and finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in individuals with chronic kidney disease (CKD) and type 2 diabetes. •Methods We randomly assigned participants with CKD (estimated glomerular filtration rate [eGFR], 30 to 90 ml/min per 1.73 m²), albuminuria (urinary albumin-to-creatinine ratio of 100 to ≤5000 mg/g), and type 2 diabetes, already on a renin–angiotensin system inhibitor, in a 1:1:1 ratio to receive finerenone (10 or 20 mg daily with empagliflozin-matching placebo), empagliflozin (10 mg daily with finerenone-matching placebo), or both. The primary outcome was the relative change in the log-transformed mean urinary albumin-to-creatinine ratio from baseline to 180 days. Safety was also evaluated. •Results At baseline, the median urinary albumin-to-creatinine ratio was 579 (interquartile range, 292 to 1092) among the 265 participants with available data, distributed evenly across groups (combination: 265, finerenone: 258, empagliflozin: 261). After 180 days, combination therapy reduced the ratio 29% more than finerenone a...
Estudia con juegos interactivos
Sube tus apuntes y genera flashcards, examenes y mas con IA
Empezar gratis